Uncertainty and excitement surround one company's cell therapy for epilepsy
Listen now
Description
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.
More Episodes
Old heuristics to acknowledge contributors-calling out first and last authors, with everyone else in between-don't work well for large collaborative and interdisciplinary projects, yet they remain the default.
Published 06/10/24
Emerging methods make it possible to combine the two tactics from opposite ends of the analytic spectrum, enabling scientists to have their cake and eat it too.
Published 06/05/24
As a new professor, I was caught off guard by one part of the job: my role as an evaluator.
Published 05/27/24